University of michigan medical school curriculum vitae

UNIVERSITY OF MICHIGAN MEDICAL SCHOOL
CURRICULUM VITAE
Departments of Neurology & Radiology
PERSONAL DATA
Home Address: 106 Woodshire Drive, Pittsburgh, PA 15215 Business Address: UPMC, Kaufmann Building, Suite 811, 3471 Fifth Avenue, Pittsburgh PA 15213.
EDUCATION

Dates Attended Name and Location
Degree Received and Major Subject
Of Institution

1973-1979

GRADUATE:
Dates Attended Name and Location
Degree Received and Major Subject
Of Institution

1979-1987

1983-1984
Programme de License, Faculté de Philosophie
POSTDOCTORAL TRAINING

Dates Attended
Name and Location
Program Director and Discipline
Of Institution

1987-1991
Section of Clinical Epidemiology Rochester, MN Advanced Fellowship in Neurology (Movement Disorders)

ACADEMIC APPOINTMENTS

Years Inclusive
Name and Location of Institution
Rank/Title

ACADEMIC ADMINISTRATIVE APPOINTMENTS
Years Inclusive
Name and Location of Institution
Director Parkinson's disease clinic, VA Medical Center R&D Committee, Alternate Chairperson, CLINICAL/HOSPITAL APPOINTMENTS

Years Inclusive
Name and Location of Institution
Title Or Position

1998-Present
SCIENTIFIC ACTIVITIES

International reviewer for New Zealand Neurological Society Member brain imaging council, Society of Nuclear Medicine Session Coordinator, Movement Disorders, Society of Nuclear Department of Veterans Affairs, Scientific reviewer. Grant reviewer, Michael J. Fox Foundation Grant reviewer, MRC (Medical Research Council), United Kingdom. Ad hoc journal reviewer: Annals of Neurology, Archives of Neurology, Brain, Cleveland Clinic Journal of Medicine, Journal of Neurology, Journal of Nuclear Medicine, Neurobiology of Aging, Pharmacopsychiatry, Progress in Neurobiology. GRANT SUPPORT

Investigator-initiated research (PI only):
1a. Scaife Family Foundation; Seed Grant; Project: Acetylcholinesterase and Glucose PET
Imaging in Parkinsonism and Dementia Period: 2/99-2/00; $25,000.
1b. VA Competitive Pilot Study; Seed Grant; Project: Acetylcholinesterase and Glucose PET
Imaging in Parkinsonism and Dementia Period: 4/99-4/00; $48,000.
1c. VA MERIT REVIEW Project: Acetylcholinesterase and Glucose PET Imaging in Parkinsonism
and Dementia (25%): 7/00-7/03; $312,600.
2. Intra-mural; Title: 99mTc-ECD brain spect normal database project. Period 1/00-4/04; $75,000.
3. Samuel and EmmaWinters Foundation; Seed Grant; Project: Cardiovascular dysautonomia in
parkinsonism and dementia; 9/99-9/01; $5,000.
4a. Veteran Research Foundation of Pittsburgh; Seed Grant; Project: Striatal D2 receptors and
amantadine treatment in parkinsonism and dementia; 1/00-1/01; $10,000.
4b. The Pittsburgh Foundation; Project: Striatal D2 receptors and amantadine in Parkinson's
disease with neurobehavioral symptoms; 7/00-7/02; $150,000.
5. NIA (5P50 AG05133 18): Therapeutic correlates of AChE PET imaging in AD; 6/00-6/05;
$416,500.
6. Scaife Family Foundation; Seed Grant; Effects of unilateral instrastriatal dopaminergic grafts in
MPTP-treated hemiparkinsonian monkeys; 10/00-10/01; $25,000.
7. NIH (P01 NS019608; (project part of program project Dr. Zigmond): PET, Posturographic and
Clinical Markers of Early PD. 5/03-4/08; $1,025,000.
8. VA MERIT REHAB REVIEW (E3270R): Neurobiological and Postural Control Mechanisms
Underlying Risk of Falling; 4/04-3/07; $771,500.
9. NIA: Executive, Postural Control and Cholinergic Functions in WMD; project part of Dr.
Studenski's Pepper Program application; 12/04-11/06; $60,000
10. NIA (: 1 P30 AG024827-01); Imaging core; Pittsburgh Older American's Independence Center; PI: Stephanie Studenski, MD, MPH 9/04-8/09; $100,000. Industry-sponsored studies (PI only):

1. Mylan Pharmaceuticals: An Open Label Study to Evaluate the Long-Term Safety and
Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of “Off” Episodes in
Patients With “On-Off” or “Wearing-Off” Effects Associated With Late-Stage Parkinson’s
Disease.; 9/00-present; $50,000.
2. Parexel Int: A Phase II, Randomized, Double-Blind, Active-Controlled Study to Determine the
Optimal Initial Titration Regime of Ropinirole CR Tablets in Parkinson’s Disease Patients Not
Receiving Other Dopaminergic Therapies; 9/01-6/03; $40,000.
3. Parexel Int: A Long-Term, Open-Label Continuation Study of Once Daily Administration of
Ropinirole CR Tablets to Patients with Parkinson’s Disease Who Completed the Previous Phase 2 Ropinirole CR Trial - 167; 3/02-present; $40,000. 4. Boehringer Ingelheim: A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson’s Disease Patients (Study for Proof of Concept in Early Parkinson’s Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE). Protocol # 1198.100; 9/03-present; $150,000. 5. A 12-week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter, Fixed Dose-Response Study to Evaluate the Efficacy and Safety of 10, 20 and 40 mg/d Oral Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa/Carbidopa Therapy; 7/04-7/05; $140,000. CERTIFICATION AND LICENSURE

SPECIALTY CERTIFICATION
Certifying
American Board or Psychiatry and Neurology (# 44021) American Board of Nuclear Medicine (#06414)
MEDICAL OR OTHER PROFESSIONAL LICENSURE:

HONORS AND AWARDS
(European Science Foundation) 'Biological markers of psychiatric and neurological illness'. Lucca, Italy. Mayo Clinic, Department of Neurology Research Award Invited for the Senior Vice-Chancellor Research Seminar (An Imaging Perspective on the Cholinergic Hypothesis in Dementia) Induction of member to ANA
MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES
Organization
Dutch Society of Clinical Neurochemistry Sigma Xi, The Scientific Research Society (Mayo Foundation Chapter) American Academy of Neurology (# 019909) American Society of Nuclear Medicine (#201951) TEACHING ACTIVITIES

Medical students
1/83-6/83:
Tutor of first year medical students. University of Nijmegen, the Netherlands. Supervisor research assignments medical students, University of Limburg, Teacher of block ‘Head Injury’, Neurology, Medical School; Proctor for medical students; Mayo Medical School. 1998-present: Teacher in Neuroscience course, Medical students MS-II, 1998-present: Teacher in Clinical Skills Course, Medical Students MS-II, Teacher Clinical Neurology course, Neurology residents Teacher Nuclear Medicine rounds, Radiology residents Teacher in Neuroscience course, Post-Graduate Students, 2000-present: Teacher in Neuroscience course, Medical students MS-II, 2000-present: Teacher in Clinical Skills Course, Medical Students MS-II, 2000-present: Teacher in Clinical Neuroscience Clerkship, Medical Students MS-III-IV, Teacher in Clinical Neuroscience Integrated Life Sciences Course; Medical Teacher in Disabilities Medicine Course; Medical Students I-II, University of Teacher in Master of Occupational Therapy (MOT) program, Parkinson's disease School of Health and Rehabilitation Sciences, University of Pittsburgh
Longitudinal clerkship MD/PhD program University of Pittsburgh:
5-6/2000: Sara

Neurology resident special elective movement disorders:
12/2001:

Pediatric neurology resident elective movement disorders:
3/2004:

Neurology fellow:
2003-2004:
Eric Farbman, MD, movement disorders fellow, University of Pittsburgh & VA movement disorders clinics.
Neurosurgery fellow:
1-4/2001:

Geriatric medicine fellows St Margaret Hospital:
1/2002:

Post-graduate Neuroscience students externship:

Neurology resident research mentors:
2/2002: Uma
COMMITTEE AND ADMINISTRATIVE SERVICE

Member Scientific Review Committee, Department of Member Residency Recruitment Committee, Department of Department of Veteran Affairs; Special Positron Emission Department of Veteran Affairs; PET/CT scan advisory group Review consultant VA MERIT program, Subcommittee for Mental Health and Behavioral Sciences, Department of Veterans Affairs, Washington, DC.

Source: http://www.aranae.com/nnirg/NBohnenCV.pdf